Oxford medical case reports · 2026
Immune checkpoint inhibitor-associated hepatotoxicity and ileitis: a diagnostic challenge in a patient on long-term nivolumab therapy.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shahzad Farah, Shahzad Muhammad, Tariq Maryam, Fatima Mushayyada, Thada Pawan Kumar, Niazi Muhammad Uzair Khan, Wahab Abdul, Shahzad Usman
Аннотация
INTRODUCTION: Immune checkpoint inhibitors (ICIs) improve cancer outcomes but may cause immune-related adverse events (irAEs). Nivolumab, an anti-PD-1 agent, is associated with hepatotoxicity and gastrointestinal toxicity.
CASE PRESENTATION: A 33-year-old American male with anaplastic large cell lymphoma of the lung, maintained on nivolumab monotherapy for five years, presented in late 2024 with fever (102.8°F), tachycardia (130 bpm), fatigue, nausea, vomiting, and abdominal discomfort. Laboratory tests revealed mild transaminitis; infectious workup was negative. CT imaging showed mild hepatic steatosis, distal ileitis, and mesenteric lymphadenopathy. Suspected nivolumab toxicity led to permanent discontinuation of therapy and initiation of high-dose corticosteroids, resulting in rapid improvement. He was discharged on day four with a steroid taper and TMP-SMX prophylaxis but was lost to follow-up.
CONCLUSION: This case emphasizes the potential for delayed nivolumab-induced hepatotoxicity and ileitis, underscoring the importance of early recognition and prompt management of late-onset irAEs.
CASE PRESENTATION: A 33-year-old American male with anaplastic large cell lymphoma of the lung, maintained on nivolumab monotherapy for five years, presented in late 2024 with fever (102.8°F), tachycardia (130 bpm), fatigue, nausea, vomiting, and abdominal discomfort. Laboratory tests revealed mild transaminitis; infectious workup was negative. CT imaging showed mild hepatic steatosis, distal ileitis, and mesenteric lymphadenopathy. Suspected nivolumab toxicity led to permanent discontinuation of therapy and initiation of high-dose corticosteroids, resulting in rapid improvement. He was discharged on day four with a steroid taper and TMP-SMX prophylaxis but was lost to follow-up.
CONCLUSION: This case emphasizes the potential for delayed nivolumab-induced hepatotoxicity and ileitis, underscoring the importance of early recognition and prompt management of late-onset irAEs.